Bill & Melinda Gates Foundation Trust
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people's health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people - especially those with the fewest resources - have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Jeff Raikes and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.
-
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
-
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
-
GSK (GSK) and Vir Biotechnology (VIR) Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab
-
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab
-
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab
-
GSK (GSK), Vir Biotechnology (VIR) Confirms FDA Emergency Use Authorization for COVID Treatment Sotrovimab
-
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
-
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
-
CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
-
Vir Bio (VIR), GSK (GSK) Announce EMA Issues Positive Scientific Opinion on Sotrovimab For Early Treatment of COVID-19
-
EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
-
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
-
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
-
GSK (GSK) and Vir Biotechnology (VIR) Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
-
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
-
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
-
Eli Lilly & Co. (LLY), Vir Biotech (VIR) & GlaxoSmithKline (GSK) Report Positive Topline Data from Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
GlaxoSmithKline (GSK), Vir Biotechnology Inc. (VIR) Submit Emergency Use Request with FDA for VIR-7831 for the Early Treatment of COVID-19
-
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
-
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
-
Vir Biotechnology (VIR) Gains 50% as VIR-7831 Reduces Hospitalization and Risk of Death from COVID-19
-
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
-
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
-
Vir Biotechnology Inc. (VIR) and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
-
Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
-
Vir Biotechnology Inc. (VIR) Begins Phase 1 Clinical Trial to Evaluate Novel Vaccine Platform
-
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2019 Financial Results
-
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2019 Financial Results
